-
PD-L1 in Cancer Immunotherapy: Key Insights(Post)
PD-L1 in Cancer Immunotherapy: Insights from Recent ResearchRecent advancements in cancer immunotherapy have underscored the critical role of programmed death-ligand 1 (PD-L1) in mediating immune evas
LPS ELISA Troubleshooting: The Importance of Sample Nature(Post)Quick answer A researcher measuring circulating lipopolysaccharide (LPS) in human serum with our LPS ELISA saw almost no color, even after 30 minutes with substrate. Samples had been test
COVID-19 (SARS-CoV-2) Assay Tests(Post)Rapid Antibody & Antigen tests available from Assay Genie
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Dupilumab: Transforming Immunotherapy and Skin Disease Management(Post)What You Need to Know About DupilumabWhat is Dupilumab?Dupilumab is a fully human monoclonal antibody designed to treat various chronic inflammatory diseases by inhibiting key cytokines
CTLA-4 in Breast Cancer: Insights for Immunotherapy(Post)The Role of CTLA-4 in Breast Cancer: Implications for ImmunotherapyBreast cancer (BC) remains one of the most prevalent malignancies affecting women worldwide, with significant morbidity and mortality
DNA Assembly Cloning(Page) TA Cloning(Page) Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Lusvertikimab: Unveiling the Potential in Immuno-Oncology(Post)What You Need to Know About LusvertikimabWhat is Lusvertikimab?Lusvertikimab is a monoclonal antibody designed to inhibit the IL-4 receptor, a key player in regulating immune responses,
Lot-zu-Lot-Variabilität: Wann Sie neue Chargen wirklich prüfen müssen(Post)Lot-zu-Lot-Variabilität: Wann Sie neue Chargen wirklich prüfen müssen Ja, Lot-zu-Lot-Variabilität ist ein reales analytisches Risiko und keine theoretische Fußnote in einem Qualitätshandbuch. Prüfen
Galectin Therapeutics(Post)Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis (IPF) is a chronic, irreversible and ultimately fatal disease characterized by prog
Innate Immune System Explained: Step-by-Step Process & Key Concepts(Post)Immunology · Cell BiologyCells of the Innate Immune System: Types, Functions and MarkersThe innate immune system responds within minutes, without prior exposure, using cells that recognise conserved m
10 reasons why you should do a science outreach event(Post)I'll start this post off with a story. When I was half way through my PhD and I had found my passion for science communication, I approached my supervisor for the first time to ask “Can I ha
Antibiotic Resistance: The Growing Threat to Human Health(Post)Antibiotic resistance is a growing problem in the world today. Antibiotics are becoming less and less effective as bacteria evolve to resist them. This poses a serious threat to human healt
Cabiralizumab: Unlocking the Potential of Anti-CSF1R Therapy(Post)What You Need to Know About CabiralizumabWhat is Cabiralizumab?Cabiralizumab is a monoclonal antibody targeting the colony-stimulating factor-1 receptor (CSF1R), developed for treating c
Fezakinumab: Exploring Its Mechanism and Clinical Potential(Post)Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe
Eldelumab: Unlocking the Potential of Anti-TNFSF14 in Inflammatory Diseases(Post)Quick Facts About EldelumabWhat is Eldelumab?Eldelumab is a monoclonal antibody targeting TNFSF14 (LIGHT), a key regulator in immune system signaling, with potential applications in infl